Exhibit 107
F-3
(Form Type)
PURPLE BIOTECH LTD.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type | Security Class Title(1)(2) | Fee Calculation or Carry Forward Rule | Amount Registered(1)(2) | Proposed Maximum Offering Price Per Security(3)(4) | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||||||||||||||||
| Newly Registered Securities | ||||||||||||||||||||||||||||
| Fees to Be Paid | Equity | Ordinary Shares, no par value represented by American Depositary Shares | Rule 457(c) | 22,151,900 | $ | 2.095 | $ | 46,408,230.50 | $ | 0.00011020 | $ | 5,114.19 | ||||||||||||||||
| Fees Previously Paid | - | - | - | - | - | - | - | - | ||||||||||||||||||||
| Total Offering Amounts | $ | 46,408,230.50 | $ | 5,114.19 | ||||||||||||||||||||||||
| Total Fees Previously Paid | $ | 0.00 | ||||||||||||||||||||||||||
| Total Fee Offsets | $ | 0.00 | ||||||||||||||||||||||||||
| Net Fee Due | $ | 5,114.19 | ||||||||||||||||||||||||||
| (1) | The ordinary shares, no par value, or Ordinary Shares, registered hereby may be represented by American Depositary Shares, or ADSs. ADSs evidenced by American depositary receipts issuable upon deposit of the Ordinary Shares registered hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-207858). Each ADS represents 10 Ordinary Shares. |
| (2) | Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the Ordinary Shares registered hereby also include an indeterminate number of additional Ordinary Shares as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions. |
| (3) | Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act, based upon the average of the high and low sales prices of the Registrant’s ADSs as reported on the Nasdaq Capital Market on March 20, 2023. |
| (4) | The Registrant will not receive any proceeds from the sale of its Ordinary Shares by the selling shareholders named in the prospectus contained in this Registration Statement on Form F-3. |
